Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Research analysts at HC Wainwright upped their Q2 2026 earnings estimates for Celldex Therapeutics in a report released on Friday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will earn ($1.04) per share for the quarter, up from their prior estimate of ($1.30). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($4.87) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($1.22) EPS, FY2026 earnings at ($4.56) EPS and FY2027 earnings at ($5.46) EPS.
CLDX has been the topic of several other reports. The Goldman Sachs Group increased their price objective on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Wolfe Research raised shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective on the stock in a report on Monday, March 23rd. Barclays increased their price objective on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a report on Friday. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.
Celldex Therapeutics Stock Down 5.0%
CLDX opened at $32.28 on Tuesday. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -7.58 and a beta of 0.98. Celldex Therapeutics has a 52-week low of $18.47 and a 52-week high of $35.79. The firm’s fifty day simple moving average is $31.78 and its two-hundred day simple moving average is $27.95.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.80 million.
Hedge Funds Weigh In On Celldex Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Segall Bryant & Hamill LLC lifted its stake in shares of Celldex Therapeutics by 36.3% in the third quarter. Segall Bryant & Hamill LLC now owns 528,597 shares of the biopharmaceutical company’s stock worth $13,675,000 after buying an additional 140,709 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Celldex Therapeutics by 4.6% in the third quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company’s stock worth $21,099,000 after buying an additional 35,575 shares in the last quarter. Propel Bio Management LLC purchased a new position in shares of Celldex Therapeutics in the third quarter worth about $4,010,000. Eventide Asset Management LLC lifted its stake in shares of Celldex Therapeutics by 37.1% in the third quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after buying an additional 502,909 shares in the last quarter. Finally, Braidwell LP acquired a new stake in Celldex Therapeutics during the third quarter worth about $15,307,000.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.
Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.
Featured Stories
- Five stocks we like better than Celldex Therapeutics
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
